MedTrace Logo

MIRABEGRON AND UAS OUTCOMES DURING RIRS

NCT07566416 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 131

Last updated 2026-05-14

No results posted yet for this study

Summary

The aim of this study is to evaluate whether there is a difference in the passage rate of the ureteral access sheath between patients who used mirabegron (a beta-3 receptor agonist) for overactive bladder and those who underwent retrograde intrarenal surgery for kidney stones, and those who did not use mirabegron. Considering that beta-3 receptors in the smooth muscle of the ureter cause relaxation in the ureter, the hypothesis that the passage rate of the access sheath increases in those using mirabegron, thus facilitating access to kidney stones and improving surgical success, will be investigated.

Conditions

  • Kidney Stone
  • Retrograde Intrarenal Surgery (RIRS)
  • Ureteral Access Sheath

Interventions

PROCEDURE

Retrograde intrarenal surgery

In our study, we evaluated the üreteral access sheath insertion rate in patients already using mirabegron for overactive bladder and scheduled for RIRS surgery for kidney stones. No additional intervention was performed beyond the routine surgical procedure.

Sponsors & Collaborators

  • Ankara Training and Research Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-10-30
Completion
2025-02-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07566416 on ClinicalTrials.gov